NCT02232633View on ClinicalTrials.gov

A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 14, 2017

Study Completion Date

December 14, 2017

Conditions
Hepatocellular CarcinomaCholangiocarcinoma
Interventions
DRUG

BBI503

Trial Locations (3)

T2N 4N2

University of Calgary, Calgary

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

Unknown

Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT02232633 - A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer | Biotech Hunter | Biotech Hunter